Kardigan, Inc (KARD) files for proposed Nasdaq IPO

Kardigan, Inc on Tuesday filed for a proposed Nasdaq IPO under the ticker "KARD."\

The company describes itself as: "Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.

Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy.

Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes."

J.P. Morgan, Jefferies, Leerink Partners and TD Cowen will serve as underwriters.

You May Also Be Interested In

• CoVolt Power files for proposed IPO
• Applied Optoelectronics sets up $600M at-the-market stock offering
• Home Depot expands executive roles, grants $500K in restricted stock